Embark Phase 3 clinical trial

[chefjlu]

Came across this today --- health.harvard.edu/blog/aft...

[Researcher50]

Think Maxone had posted this also, but my question now would be whether apalutamide would be better than enzalutamide in this setting as it has been shown to have greater efficiency?

[Researcher50]

I googled a comparison between the two and this is what came up. pubmed.ncbi.nlm.nih.gov/370...

[billfenley2 in reply to Researcher50]

Sorry if this is not appropriate here, but the Embark 3 study was with non-metastatic patients (supposedly) and this comparison is with metastatic patients.

[Researcher50 in reply to billfenley2]

The devil is in the details! Thank you! I was trying to extrapolate a bit. The Embark study says "The investigators already knew from earlier studies that enzalutamide delays further progression and lengthens survival for men with metastatic prostate cancer", which is what lead them to try it earlier in a BCR setting. So my thought was if enzalutamide worked well in this setting, then perhaps apalutamide might be even more effective based on the comparison of the two. No studies, just wondering if that might make sense.

[billfenley2 in reply to Researcher50]

Good thoughts, Researcher. A couple of months ago I was talking about this with my MO, Andy Armstrong (Duke). Xtandi hadn't been FDA approved for this use yet (it was so approved in November) so I asked him about Erleada, but he was dismissive of it for this use, at least in terms of its credentials compared to the gold-plated Embark trial endorsing Xtandi.

[Survivor86]

Thanks Chef! The Embark 3 study offers great hope for many of us who follow this forum—the perfect gift this holiday season. Wishing you all the best in the New Year!